Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Clin Cancer Res
    May 2026
  1. GRANHOJ JS, Mannering SMH, Madsen K, W Hendel H, et al
    Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.
    Clin Cancer Res. 2026 May 18. doi: 10.1158/1078-0432.CCR-25-4097.
    >> Share

  2. PAKVISAL N, Wongkongkathep P, Bunrasmee W, Sodsai P, et al
    The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma.
    Clin Cancer Res. 2026 May 7. doi: 10.1158/1078-0432.CCR-25-4271.
    >> Share

    April 2026
  3. SCHLAAK M, Cimminiello C, Pigozzo J, Lee J, et al
    MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
    Clin Cancer Res. 2026 Apr 21. doi: 10.1158/1078-0432.CCR-25-3951.
    >> Share

  4. GARRALDA E, Markert C, Moreno V, Calvo E, et al
    A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma.
    Clin Cancer Res. 2026 Apr 7. doi: 10.1158/1078-0432.CCR-25-4478.
    >> Share

    March 2026
  5. NINMER EK, Zhu H, Sarkar A, Chianese-Bullock KA, et al
    Impact of GM-CSF and two-site vaccination on clinical outcomes after multipeptide vaccination for melanoma: long-term analysis of a randomized phase II trial.
    Clin Cancer Res. 2026 Mar 18. doi: 10.1158/1078-0432.CCR-25-4606.
    >> Share

  6. LIN Z, Tang C, Liu T, Wang X, et al
    Comparison of [18F]PFPN and [18F]FDG PET in mucosal melanoma: diagnostic performance, staging impact, and correlation with molecular markers.
    Clin Cancer Res. 2026 Mar 4. doi: 10.1158/1078-0432.CCR-25-3953.
    >> Share

    February 2026
  7. ANSSTAS G, Khaddour K, Sudhaman S, Lin K, et al
    Longitudinal ctDNA monitoring for post-surgical disease surveillance in patients with stage I-IIIB melanoma.
    Clin Cancer Res. 2026 Feb 3. doi: 10.1158/1078-0432.CCR-25-3643.
    >> Share

    January 2026
  8. DUMMER R, Deng S, Xie T, Pathan N, et al
    Exploratory Analysis of Biomarkers and Treatment Outcomes From the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-3262.
    >> Share

  9. BARGER LN, Wang D, Saravia AL, Mezzano V, et al
    Population analysis and immunologic landscape of melanoma in people living with HIV.
    Clin Cancer Res. 2026 Jan 8. doi: 10.1158/1078-0432.CCR-25-3148.
    >> Share

    December 2025
  10. RAMELYTE E, Kott J, Lawless AR, Ciernik A, et al
    Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma.
    Clin Cancer Res. 2025 Dec 12. doi: 10.1158/1078-0432.CCR-25-2274.
    >> Share

    October 2025
  11. WIGGINS JM, Zhang Q, Zhang Y, Vand-Rajabpour F, et al
    Tumor microRNA signatures associate with stage II/III melanoma patient outcomes.
    Clin Cancer Res. 2025 Oct 20. doi: 10.1158/1078-0432.CCR-24-3785.
    >> Share

    September 2025
  12. SATO T, Butler MO, Piperno-Neumann S, Hassel JC, et al
    Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients.
    Clin Cancer Res. 2025 Sep 12. doi: 10.1158/1078-0432.CCR-25-1513.
    >> Share

  13. VERGARA IA, Maher NG, Potter AJ, Paver EC, et al
    Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors.
    Clin Cancer Res. 2025;31:3742-3753.
    >> Share

    August 2025
  14. NOH KW, Tolkach Y, Helbig D, Mitchell Barroso V, et al
    Multimodal approach predicts relapse upon cessation of immune checkpoint inhibitors in advanced melanoma.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0889.
    >> Share

  15. FA'AK F, Coudray N, Jour G, Ibrahim M, et al
    Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2025;31:3526-3536.
    >> Share

    July 2025
  16. RIBAS A, Milhem MM, Hoimes CJ, Amin A, et al
    Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced Melanoma.
    Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0987.
    >> Share

  17. HU L, Fan C, Bross P, Das A, et al
    FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapy.
    Clin Cancer Res. 2025 Jul 23. doi: 10.1158/1078-0432.CCR-25-0880.
    >> Share

  18. LIPSON EJ, Dolfi S, Tang H, Tawbi HA, et al
    Unravelling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047.
    Clin Cancer Res. 2025 Jul 3. doi: 10.1158/1078-0432.CCR-24-2499.
    >> Share

    June 2025
  19. DAVAR D, Eroglu Z, Perez CL, Di Pace B, et al
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.
    Clin Cancer Res. 2025 Jun 24:OF1-OF10. doi: 10.1158/1078-0432.CCR-25-0884.
    >> Share

  20. BHANJA D, Zhu J, Wilding H, Benavides-Vasquez J, et al
    A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy.
    Clin Cancer Res. 2025 Jun 2. doi: 10.1158/1078-0432.CCR-24-2681.
    >> Share

    May 2025
  21. FLAHERTY KT, Aplin AE, Davies MA, Hacohen N, et al
    Facts & Hopes: towards the next quantum leap in melanoma.
    Clin Cancer Res. 2025 May 23. doi: 10.1158/1078-0432.CCR-25-0278.
    >> Share

  22. TARHINI AA, Obermayer A, Lee SJ, LaFramboise WA, et al
    Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk Melanoma.
    Clin Cancer Res. 2025 May 20. doi: 10.1158/1078-0432.CCR-24-3980.
    >> Share

  23. VERDEGAAL EME, Verpoorte ALC, van der Kooij MK, de Bruin L, et al
    Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires interferon-alpha.
    Clin Cancer Res. 2025 May 6. doi: 10.1158/1078-0432.CCR-24-4322.
    >> Share

    April 2025
  24. LI Y, Cui Z, Song X, Chen Y, et al
    Single-cell transcriptomic landscape deciphers intratumoral heterogeneity and subtypes of acral and mucosal melanoma.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3164.
    >> Share

    March 2025
  25. DUMMER R, Sandhu S, Miller WH, Butler MO, et al
    Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma.
    Clin Cancer Res. 2025 Mar 19. doi: 10.1158/1078-0432.CCR-24-0254.
    >> Share

  26. LI X, Zhang X, Zhao S, Pei S, et al
    The dynamically evolving cell states and ecosystem from benign nevi to melanoma.
    Clin Cancer Res. 2025 Mar 17. doi: 10.1158/1078-0432.CCR-24-2971.
    >> Share

    February 2025
  27. WANG C, Niu X, Xia T, Wang P, et al
    Predicting c-KIT Inhibitor Efficacy in Patient-Derived Models of Sinonasal Mucosal Melanomas through Integrated Histogram Analysis of Whole-Tumor DKI, IVIM, and DCE-MRI.
    Clin Cancer Res. 2025 Feb 12. doi: 10.1158/1078-0432.CCR-24-3765.
    >> Share

    December 2024
  28. FISCHER GM, Lamba N, Vogelzang J, Aizer A, et al
    Genomic profiling reveals SMARCA4 mutations are associated with shorter overall and intracranial progression free survival in melanoma brain metastasis patients.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-0301.
    >> Share

  29. LEE S, Hamid O, Jotte R, Zakharia Y, et al
    Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478.
    >> Share

    October 2024
  30. TARHINI AA, Eroglu Z, Eljilany I, Zager JS, et al
    Neoadjuvant intratumoral plasmid interleukin-12 electro-gene-transfer and nivolumab in patients with operable locoregionally advanced melanoma.
    Clin Cancer Res. 2024 Oct 17. doi: 10.1158/1078-0432.CCR-24-2768.
    >> Share

  31. GIDE TN, Mao Y, Scolyer RA, Long GV, et al
    Tissue-based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma.
    Clin Cancer Res. 2024 Oct 7. doi: 10.1158/1078-0432.CCR-24-1109.
    >> Share

    September 2024
  32. MA KL, Mitchell TC, Dougher M, Sharon CE, et al
    Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival.
    Clin Cancer Res. 2024 Sep 9. doi: 10.1158/1078-0432.CCR-23-3775.
    >> Share

    August 2024
  33. SMITHY JW, Kalvin HL, Ehrich FD, Shah R, et al
    Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
    Clin Cancer Res. 2024;30:3407-3415.
    >> Share

  34. MONSON KR, Ferguson R, Handzlik JE, Xiong J, et al
    Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma.
    Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-0900.
    >> Share

    July 2024
  35. YAKKALA C, Corria-Osorio J, Kandalaft L, Denys A, et al
    Cryoablation does not significantly contribute to systemic effector immune responses in poorly immunogenic B16F10 melanoma model.
    Clin Cancer Res. 2024 Jul 18. doi: 10.1158/1078-0432.CCR-24-0371.
    >> Share

  36. ZHAO Y, Hu Z, Bathena SP, Keidel S, et al
    Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors.
    Clin Cancer Res. 2024;30:3050-3058.
    >> Share

  37. STINSON JA, P Barbosa MM, Sheen A, Momin N, et al
    Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs.
    Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0861.
    >> Share

    June 2024
  38. AUNG TN, Warrell J, Martinez-Morilla S, Gavrielatou N, et al
    Spatially informed gene signatures for response to immunotherapy in melanoma.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-3932.
    >> Share

  39. D'ALISE AM, Leoni G, Cotugno G, Siani L, et al
    Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses.
    Clin Cancer Res. 2024;30:2412-2423.
    >> Share

    May 2024
  40. VENTIN M, Cattaneo G, Arya S, Jia J, et al
    Chimeric Antigen Receptor T Cell with an Inducible Caspase 9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.
    Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-24-0071.
    >> Share

  41. EMBABY A, Huijberts SCFA, Wang L, Leite de Oliveira R, et al
    A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma.
    Clin Cancer Res. 2024 May 13. doi: 10.1158/1078-0432.CCR-23-3171.
    >> Share

    January 2024
  42. ANDERSON TM, Chang BH, Huang AC, Xu X, et al
    FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
    Clin Cancer Res. 2024 Jan 24:OF1-OF10. doi: 10.1158/1078-0432.CCR-23-2390.
    >> Share

    November 2023
  43. SHEN A, Arbesman M, Lodha R, Rayman P, et al
    Clinical and Immunologic Features of Germline Pathogenic Variant (gPV) Positive Patients with Melanoma.
    Clin Cancer Res. 2023 Nov 30. doi: 10.1158/1078-0432.CCR-23-1964.
    >> Share

    October 2023
  44. PATEL SP, Othus M, Chae YK, Dennis MJ, et al
    A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia.
    Clin Cancer Res. 2023 Oct 26. doi: 10.1158/1078-0432.CCR-23-2293.
    >> Share

  45. ZILA N, Eichhoff OM, Steiner I, Mohr T, et al
    Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy.
    Clin Cancer Res. 2023 Oct 20. doi: 10.1158/1078-0432.CCR-23-0562.
    >> Share

  46. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    >> Share

  47. BETOF WARNER A, Luke JJ
    CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II.
    Clin Cancer Res. 2023;29:3829-3831.
    >> Share

    September 2023
  48. MONBERG TJ, Borch TH, Svane IM, Donia M, et al
    TIL Therapy: Facts and Hopes.
    Clin Cancer Res. 2023;29:3275-3283.
    >> Share

    August 2023
  49. VAN DEN BULK J, Verdegaal EME, van der Ploeg M, Visser M, et al
    Neoantigen targetability in progressive advanced melanoma.
    Clin Cancer Res. 2023 Aug 4:CCR-23-1106. doi: 10.1158/1078-0432.CCR-23-1106.
    >> Share

  50. WEISS SA, Sznol M, Shaheen M, Berciano-Guerrero MA, et al
    A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0475. doi: 10.1158/1078-0432.CCR-23-0475.
    >> Share

    July 2023
  51. SMITHY JW, Luke JJ
    CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade.
    Clin Cancer Res. 2023;29:2345-2347.
    >> Share

    June 2023
  52. AUGUSTIN RC, Luke JJ
    PD1 monotherapy reigns supreme in adjuvant melanoma...but for how long?
    Clin Cancer Res. 2023 Jun 28:CCR-23-1194. doi: 10.1158/1078-0432.CCR-23-1194.
    >> Share

  53. ELLINGSEN EB, O'Day S, Mezheyeuski A, Gromadka A, et al
    Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.
    Clin Cancer Res. 2023 Jun 28:CCR-23-0416. doi: 10.1158/1078-0432.CCR-23-0416.
    >> Share

  54. TOKER J, Iorgulescu JB, Ling AL, Villa GR, et al
    Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2023;29:2226-2238.
    >> Share

  55. FOX BA, Urba WJ, Jensen SM, Page DB, et al
    Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies.
    Clin Cancer Res. 2023;29:2173-2175.
    >> Share

  56. STINSON JA, Sheen A, Momin N, Hampel J, et al
    Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas.
    Clin Cancer Res. 2023;29:2110-2122.
    >> Share

    May 2023
  57. HOROWITCH B, Lee DY, Ding M, Martinez-Morilla S, et al
    Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients.
    Clin Cancer Res. 2023 May 26:CCR-23-0215. doi: 10.1158/1078-0432.CCR-23-0215.
    >> Share

  58. STUPIA S, Heeke C, Bruggemann A, Zaremba A, et al
    HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNgamma cross-resistance.
    Clin Cancer Res. 2023 May 18:CCR-23-0099. doi: 10.1158/1078-0432.CCR-23-0099.
    >> Share

  59. FANE ME, Ecker BL, Kaur A, Marino GE, et al
    Correction: sFRP2 Supersedes VEGF as an Age-related Driver of Angiogenesis in Melanoma, Affecting Response to Anti-VEGF Therapy in Older Patients.
    Clin Cancer Res. 2023;29:2012.
    >> Share

  60. DRAGHI A, Presti M, Jensen AWP, Chamberlain CA, et al
    Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.
    Clin Cancer Res. 2023 May 1:CCR-22-3853. doi: 10.1158/1078-0432.CCR-22-3853.
    >> Share

    April 2023
  61. LARKIN J, Del Vecchio M, Mandala M, Gogas H, et al
    Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.
    Clin Cancer Res. 2023 Apr 14:CCR-22-3145. doi: 10.1158/1078-0432.CCR-22-3145.
    >> Share

  62. OLSON DJ, Luke JJ
    Myeloid Maturity: ATRA to Enhance Anti-PD-1?
    Clin Cancer Res. 2023;29:1167-1169.
    >> Share

    March 2023
  63. KOTTSCHADE LA, Pond GR, Olszanski AJ, Zakharia Y, et al
    SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
    Clin Cancer Res. 2023 Mar 31:CCR-22-3207. doi: 10.1158/1078-0432.CCR-22-3207.
    >> Share

  64. ROBERT C, Lebbe C, Lesimple T, Lundstrom E, et al
    Phase I Study of Androgen Deprivation Therapy in Combination with Anti-PD-1 in Melanoma Patients Pretreated with Anti-PD-1.
    Clin Cancer Res. 2023;29:858-865.
    >> Share

  65. FENTON GA, Mitchell DA
    Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic.
    Clin Cancer Res. 2023;29:843-857.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016